<DOC>
	<DOCNO>NCT01329276</DOCNO>
	<brief_summary>Computational Fluid Dynamics ( CFD ) new functional imaging method . Since CFD sensitive detect small change , might worthwhile study acute effect formoterol budesonide combination therapy ( Symbicort® forte Turbohaler® ) upper airway dimension severe COPD patient ( GOLD III ) . The increased sensitivity technique make possible detect change airway caliber early stage . The regional distribution resistance change parameter provide insight mode action product .</brief_summary>
	<brief_title>Assess Particle Deposition Acute Effects Symbicort® Forte Turbohaler® ) COPD Patients .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Patients document COPD base follow criterion : Smoking history least 10 packyears decrease Tiffeneau index ( FEV1/ ( F ) VC &lt; 0.70 ) . 2 . Patients present severe COPD FEV1 50 30 % predict ( GOLD 3 ) . 3 . Male female patient age ≥ 40 year . 4 . Patients treat accord GOLD guideline study start . 5 . Patients , opinion investigator , cooperative attitude ability train correctly use TurbohalerR . 6 . Maintained stable respiratory medication 6 week prior visit 1 . 7 . Written inform consent obtain . 1 . Pregnancy , breastfeed plan pregnancy study . Fertile woman use acceptable contraceptive measure , judge investigator . 2 . Inability carry pulmonary function test . 3 . A respiratory infection exacerbation COPD four week prior screen . 4 . Any significant disease disorder , opinion investigator , may either put patient risk participation study , influence result study , patient 's ability participate study 5 . A history asthma , cystic fibrosis , central bronchiectasis , interstitial lung disease pulmonary thromboembolic disease . 6 . Cancer chronic disease poor prognosis and/or affect patient status . 7 . A history thoracotomy pulmonary resection . 8 . Allergy , sensitivity intolerance study drug and/or study drug formulation ingredient . 9 . History alcohol drug abuse . 10 . Patients unlikely comply protocol unable understand nature , scope possible consequence study . 11 . Patients receive investigational new drug within last 4 week prior screen visit . 12 . Patients treat nonpermitted concomitant medication ( see 7.2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>COPD</keyword>
	<keyword>Symbicort</keyword>
	<keyword>Turbohaler</keyword>
	<keyword>Computational Fluid Dynamics</keyword>
	<keyword>Functional Imaging</keyword>
	<keyword>Budesonide</keyword>
	<keyword>Formoterol</keyword>
</DOC>